Viatris Inc. (VTRS)

NMS – Real vaqt narxi. Valyuta: USD

16.33

+0.26 (1.62%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

16.11

-0.22 (-1.32%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

05.06.2026

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.

04.06.2026

Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

19.05.2026

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.

18.05.2026

Here's Why Viatris (VTRS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

18.05.2026

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026.

13.05.2026

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

12.05.2026

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videolar

No Data

There is no data to display

Press-relizlar

18.05.2026

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

07.05.2026

Viatris Reports First-Quarter 2026 Financial Results

Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025 Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in Japan Continues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026 Reaffirms 2026 Financial Guidance [1] PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced its first-quarter 2026 financial results. Executive Commentary "We delivered a strong first quarter, reflecting disciplined execution across our global businesses," said Scott A.

05.05.2026

Viatris Announces Quarterly Dividend

PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.

04.05.2026

Viatris Announces Chief Financial Officer Transition

Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO PITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity. Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor.

Viatris Inc. (VTRS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Viatris Inc. (VTRS)

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Here's Why Viatris (VTRS) is a Strong Value Stock

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

Here's Why Viatris (VTRS) is a Strong Momentum Stock

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videolar

No Data

Press-relizlar

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Viatris Reports First-Quarter 2026 Financial Results

Viatris Announces Quarterly Dividend

Viatris Announces Chief Financial Officer Transition

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Here's Why Viatris (VTRS) is a Strong Value Stock

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

Here's Why Viatris (VTRS) is a Strong Momentum Stock

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videolar

No Data

Press-relizlar

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Viatris Reports First-Quarter 2026 Financial Results

Viatris Announces Quarterly Dividend

Viatris Announces Chief Financial Officer Transition

Search stocks

Viatris Inc. (VTRS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Viatris Inc. (VTRS)

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Here's Why Viatris (VTRS) is a Strong Value Stock

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

Here's Why Viatris (VTRS) is a Strong Momentum Stock

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videolar

No Data

Press-relizlar

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Viatris Reports First-Quarter 2026 Financial Results

Viatris Announces Quarterly Dividend

Viatris Announces Chief Financial Officer Transition

3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Here's Why Viatris (VTRS) is a Strong Value Stock

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

Here's Why Viatris (VTRS) is a Strong Momentum Stock

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Videolar

No Data

Press-relizlar

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

Viatris Reports First-Quarter 2026 Financial Results

Viatris Announces Quarterly Dividend

Viatris Announces Chief Financial Officer Transition